Boehme AK, Esenwa C, Elkind MS Stroke Risk Factors, Genetics, and Prevention. Circ Res. 2017 Feb 3;120(3):472-495. doi: 10.1161/CIRCRESAHA.116.308398. Review.
Carey RM, Muntner P, Bosworth HB, Whelton PK Prevention and Control of Hypertension: JACC Health Promotion Series. J Am Coll Cardiol. 2018 Sep 11;72(11):1278-1293. doi: 10.1016/j.jacc.2018.07.008. Review.
Chu AH, Ng SH, Koh D, Müller-Riemenschneider F Reliability and Validity of the Self- and Interviewer-Administered Versions of the Global Physical Activity Questionnaire (GPAQ). PLoS One. 2015 Sep 1;10(9):e0136944. doi: 10.1371/journal.pone.0136944. eCollection 2015.
Dorans KS, Mills KT, Liu Y, He J Trends in Prevalence and Control of Hypertension According to the 2017 American College of Cardiology/American Heart Association (ACC/AHA) Guideline. J Am Heart Assoc. 2018 Jun 1;7(11). pii: e008888. doi: 10.1161/JAHA.118.008888.
Finbråten HS, Wilde-Larsson B, Nordström G, Pettersen KS, Trollvik A, Guttersrud Ø Establishing the HLS-Q12 short version of the European Health Literacy Survey Questionnaire: latent trait analyses applying Rasch modelling and confirmatory factor analysis. BMC Health Serv Res. 2018 Jun 28;18(1):506. doi: 10.1186/s12913-018-3275-7.
GBD 2017 Risk Factor Collaborators Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018 Nov 10;392(10159):1923-1994. doi: 10.1016/S0140-6736(18)32225-6. Epub 2018 Nov 8. Erratum in: Lancet. 2019 Jan 12;393(10167):132. Lancet. 2019 Jun 22;393(10190):e44.
Halcomb E, Moujalli S, Griffiths R, Davidson P Effectiveness of general practice nurse interventions in cardiac risk factor reduction among adults. JBI Libr Syst Rev. 2007;5(7):407-453.
Head GA, Shaw JE, Dunstan DW, Owen N, Magliano DJ, Chadban S, Zimmet P Hypertension, white-coat hypertension and masked hypertension in Australia: findings from the Australian Diabetes, Obesity, and Lifestyle Study 3. J Hypertens. 2019 Aug;37(8):1615-1623. doi: 10.1097/HJH.0000000000002087.
Islam FM, Chakrabarti R, Islam MT, Wahab M, Lamoureux E, Finger RP, Shaw JE Prediabetes, diagnosed and undiagnosed diabetes, their risk factors and association with knowledge of diabetes in rural Bangladesh: The Bangladesh Population-based Diabetes and Eye Study. J Diabetes. 2016 Mar;8(2):260-8. doi: 10.1111/1753-0407.12294. Epub 2015 May 6.
Islam FM, Chakrabarti R, Islam SZ, Finger RP, Critchley C Factors Associated with Awareness, Attitudes and Practices Regarding Common Eye Diseases in the General Population in a Rural District in Bangladesh: The Bangladesh Population-based Diabetes and Eye Study (BPDES). PLoS One. 2015 Jul 22;10(7):e0133043. doi: 10.1371/journal.pone.0133043. eCollection 2015.
Mumu SJ, Ali L, Barnett A, Merom D Validity of the global physical activity questionnaire (GPAQ) in Bangladesh. BMC Public Health. 2017 Aug 10;17(1):650. doi: 10.1186/s12889-017-4666-0.
Saquib N, Saquib J, Ahmed T, Khanam MA, Cullen MR Cardiovascular diseases and type 2 diabetes in Bangladesh: a systematic review and meta-analysis of studies between 1995 and 2010. BMC Public Health. 2012 Jun 13;12:434. doi: 10.1186/1471-2458-12-434. Review.
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.